PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033
Phase 1
Withdrawn
- Conditions
- Obesity
- First Posted Date
- 2006-09-14
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00376285
A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease
Phase 3
Completed
- Conditions
- Gaucher Disease
- Interventions
- First Posted Date
- 2006-09-14
- Last Posted Date
- 2018-10-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT00376168
- Locations
- 🇪🇸
Hospital Universitario Miguel Servet, Zaragoza, Spain
🇮🇱Shaare Zedek Medical Center, Jerusalem, Israel
🇮🇱Rambam Medical Center, Haifa, Israel
A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety
Phase 3
Terminated
- Conditions
- Obesity
- Interventions
- Drug: CP-945,598 Treatment ADrug: CP-945,598 Treatment BDrug: Placebo
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2536
- Registration Number
- NCT00375401
- Locations
- 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 674
- Registration Number
- NCT00375674
- Locations
- 🇨🇴
Instituto Nacional de Cancerologia - ESE, Bogota, Cundinamarca, Colombia
🇮🇪Beaumont Hospital, Dublin, Ireland
🇮🇱Assaf Harofeh Medical Center, Zerifin, Israel
A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer
Phase 3
Completed
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2006-09-08
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 488
- Registration Number
- NCT00373256
- Locations
- 🇪🇸
Pfizer Investigational Site, Madrid, Spain
Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine
Phase 3
Completed
- Conditions
- Vaccines, Pneumococcal
- Interventions
- Biological: 13 valent pneumococcal conjugate vaccineBiological: 7vPnc pneumococcal conjugate vaccine
- First Posted Date
- 2006-09-08
- Last Posted Date
- 2013-02-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 666
- Registration Number
- NCT00373958
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 482
- Registration Number
- NCT00373113
- Locations
- 🇬🇧
Pfizer Investigational Site, Somerset, United Kingdom
Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2012-12-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT00372424
- Locations
- 🇮🇹
Pfizer Investigational Site, Milano, Italy
Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
Phase 3
Terminated
- Conditions
- Gastrointestinal Stromal Tumor
- Interventions
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2011-03-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 69
- Registration Number
- NCT00372567
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2011-02-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT00372775
- Locations
- 🇪🇸
Pfizer Investigational Site, Valencia, Spain
© Copyright 2025. All Rights Reserved by MedPath